Before ivosidenib approval, modified FOLFOX (mFOLFOX), which combines oxaliplatin, folinic acid, and fluorouracil, was the recommended second-line chemotherapy for advanced ICC with IDH1 mutations as per international guidelines [3, 4]. This evidence concerns the gene IDH1 and intrahepatic cholangiocarcinoma.